Pyraxolidinone CCK and gastrin antogonists and pharmaceutical formulations thereof
申请人:ELI LILLY AND COMPANY
公开号:EP0467614A1
公开(公告)日:1992-01-22
Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described.
Pyrazolidinone CCK and gastrin antagonists and pharmaceutical
申请人:Eli Lilly and Company
公开号:US05300514A1
公开(公告)日:1994-04-05
Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described.